Following the successful administration of two doses of the Pfizer BNT162b2 vaccine to most eligible adults in Israel, the country saw a remarkable drop in the number of cases of coronavirus disease 2019 (COVID-19) and hospitalizations. However, this changed as the country opened up, leading to a surge in new cases driven largely by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) delta variant.
